EP2156184A4 - Methods for diagnosing and treating prostate and lung cancer - Google Patents
Methods for diagnosing and treating prostate and lung cancerInfo
- Publication number
- EP2156184A4 EP2156184A4 EP08754314A EP08754314A EP2156184A4 EP 2156184 A4 EP2156184 A4 EP 2156184A4 EP 08754314 A EP08754314 A EP 08754314A EP 08754314 A EP08754314 A EP 08754314A EP 2156184 A4 EP2156184 A4 EP 2156184A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- diagnosing
- methods
- lung cancer
- treating prostate
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91671907P | 2007-05-08 | 2007-05-08 | |
PCT/US2008/005983 WO2008140774A2 (en) | 2007-05-08 | 2008-05-08 | Methods for diagnosing and treating prostate and lung cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2156184A2 EP2156184A2 (en) | 2010-02-24 |
EP2156184A4 true EP2156184A4 (en) | 2010-07-21 |
EP2156184B1 EP2156184B1 (en) | 2013-11-27 |
Family
ID=40002842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20080754314 Not-in-force EP2156184B1 (en) | 2007-05-08 | 2008-05-08 | Methods for diagnosing and treating prostate and lung cancer |
Country Status (7)
Country | Link |
---|---|
US (1) | US20130224209A1 (en) |
EP (1) | EP2156184B1 (en) |
JP (1) | JP2010528261A (en) |
CN (1) | CN101918836B (en) |
AU (1) | AU2008251877A1 (en) |
CA (1) | CA2686954A1 (en) |
WO (1) | WO2008140774A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2687620T3 (en) | 2007-05-04 | 2018-10-26 | Opko Diagnostics, Llc | Device and method for analysis in microfluidic systems |
AU2011261323A1 (en) * | 2010-06-04 | 2013-01-24 | The Brigham And Women's Hospital, Inc. | Treatment of inflammatory disorders |
JP5909070B2 (en) * | 2010-10-28 | 2016-04-26 | 国立大学法人 東京大学 | Method for screening drug candidate compound for Gs-coupled receptor |
MY193914A (en) * | 2012-03-05 | 2022-11-01 | Oy Arctic Partners Ab | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume |
CN102914658A (en) * | 2012-10-24 | 2013-02-06 | 高维强 | Application of CRISP3 protein on diagnosis and treatment of prostate cancer |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
WO2015106311A1 (en) * | 2014-01-17 | 2015-07-23 | Minomic International Ltd. | Cell surface prostate cancer antigen for diagnosis |
CN104090103B (en) * | 2014-03-24 | 2016-08-31 | 福州市传染病医院 | Test kit based on antibody modification ZnSe nanocrystalline detection liver cancer marker GPC3 |
PE20170298A1 (en) * | 2014-03-28 | 2017-04-18 | Opko Diagnostics Llc | COMPOSITIONS AND METHODS RELATED TO THE DIAGNOSIS OF PROSTATE CANCER |
EP2944652A1 (en) * | 2014-05-13 | 2015-11-18 | Technische Universität München | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma |
KR102461014B1 (en) * | 2014-07-14 | 2022-10-31 | 베라사이트 인코포레이티드 | Methods for Evaluating Lung Cancer Status |
EP3770274A1 (en) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
US11097005B2 (en) | 2014-12-15 | 2021-08-24 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity |
PT3253800T (en) | 2015-03-27 | 2021-04-28 | Opko Diagnostics Llc | Prostate antigen standards and uses thereof |
CN112034185A (en) * | 2020-09-11 | 2020-12-04 | 上海市胸科医院 | Application of GPR110, VEGFR and CD34 in identifying lung adenocarcinoma subtypes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074960A2 (en) * | 2000-11-08 | 2002-09-26 | Millennium Pharmaceuticals, Inc. | 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof |
WO2002086443A2 (en) * | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
WO2003009814A2 (en) * | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
WO2007047796A2 (en) * | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2795403B2 (en) * | 1986-07-30 | 1998-09-10 | 株式会社 シノテスト | Immunoassay method and device |
AU756452B2 (en) * | 1998-08-10 | 2003-01-16 | Agensys, Inc. | BPC-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells |
AU2002330482A1 (en) * | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
WO2006086578A1 (en) * | 2002-10-02 | 2006-08-17 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Internal biochemical sensing device |
JP2004279157A (en) * | 2003-03-14 | 2004-10-07 | Rohto Pharmaceut Co Ltd | Kit and method for determining focus of cancer |
US20060094046A1 (en) * | 2004-02-11 | 2006-05-04 | Arie Abo | Compositions and methods relating to angiogenesis and tumorigenesis |
WO2005085292A2 (en) * | 2004-03-03 | 2005-09-15 | Biomerieux | Method for detecting the activatable free form of psa and the use thereof for diagnosing benign pathologies of the prostate and adenocarcinoma of the prostate |
EP1831684A4 (en) * | 2004-11-30 | 2009-03-11 | Veridex Llc | Lung cancer prognostics |
US20060211059A1 (en) * | 2005-03-18 | 2006-09-21 | Taneja Samir S | Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone |
JP2007075072A (en) * | 2005-09-16 | 2007-03-29 | Satoshi Takahashi | ANTICANCER AGENT CONTAINING COMPOSITION FOR CONTROLLING FUNCTION OF PROTHYMOSIN alpha AND NUCLEIC ACID CONTAINED IN COMPOSITION FOR CONTROLLING EXPRESSION OF PROTHYMOSIN alpha GENE |
-
2008
- 2008-05-08 EP EP20080754314 patent/EP2156184B1/en not_active Not-in-force
- 2008-05-08 JP JP2010507474A patent/JP2010528261A/en active Pending
- 2008-05-08 AU AU2008251877A patent/AU2008251877A1/en not_active Abandoned
- 2008-05-08 WO PCT/US2008/005983 patent/WO2008140774A2/en active Application Filing
- 2008-05-08 CN CN200880023852.5A patent/CN101918836B/en not_active Expired - Fee Related
- 2008-05-08 CA CA 2686954 patent/CA2686954A1/en not_active Abandoned
-
2013
- 2013-01-21 US US13/746,180 patent/US20130224209A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074960A2 (en) * | 2000-11-08 | 2002-09-26 | Millennium Pharmaceuticals, Inc. | 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof |
WO2002086443A2 (en) * | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
WO2003009814A2 (en) * | 2001-07-25 | 2003-02-06 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer |
WO2007047796A2 (en) * | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
Non-Patent Citations (1)
Title |
---|
See also references of WO2008140774A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP2010528261A (en) | 2010-08-19 |
CN101918836B (en) | 2014-04-30 |
WO2008140774A9 (en) | 2010-02-11 |
AU2008251877A1 (en) | 2008-11-20 |
US20130224209A1 (en) | 2013-08-29 |
CA2686954A1 (en) | 2008-11-20 |
CN101918836A (en) | 2010-12-15 |
AU2008251877A2 (en) | 2010-02-04 |
WO2008140774A3 (en) | 2009-01-15 |
EP2156184B1 (en) | 2013-11-27 |
WO2008140774A2 (en) | 2008-11-20 |
EP2156184A2 (en) | 2010-02-24 |
AU2008251877A9 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2156184A4 (en) | Methods for diagnosing and treating prostate and lung cancer | |
PL3009148T3 (en) | Compositions and methods for treating and diagnosing cancer | |
EP2061899A4 (en) | Biomarkers for prostate cancer and methods using the same | |
EP2125887A4 (en) | Compositions and methods for diagnosing and treating cancer | |
IL197721A0 (en) | Compositions and methods for diagnosing and treating cancer | |
PL2032166T3 (en) | Compositions and methods for diagnosing and treating cancer | |
IL193842A0 (en) | Diagnostics and treatments for tumors | |
EP2000543A4 (en) | Method for the molecular diagnosis of prostate cancer and kit for implementing same | |
EP1922326A4 (en) | Biomarkers useful for diagnosing prostate cancer, and methods thereof | |
EP2367939A4 (en) | Methods for diagnosing or treating prostate cancer | |
EP2155249A4 (en) | Compositions and methods for diagnosing and treating cancer | |
EP2171086A4 (en) | Methods of diagnosing and treating cancer | |
IL197633A0 (en) | Methods for treating cancer with mva | |
EP2170180A4 (en) | Methods and apparatuses for vascular and prostate treatment | |
EP1991230A4 (en) | Methods of treating cancer | |
EP1977247A4 (en) | Methods for diagnosing and treating prostate cancer | |
EP2340851A4 (en) | Diagnosis method and therapeutic method for cancer | |
IL238394A0 (en) | Cancer treatment method | |
EP1862804A4 (en) | Method for diagnosis of prostate cancer | |
IL186980A0 (en) | Characterizing prostate cancer | |
EP2515115A4 (en) | Kit for diagnosing prostate cancer and diagnosis method | |
EP2144888A4 (en) | Methods for treating cancer | |
EP2099491A4 (en) | Compositions and methods for diagnosing and treating cancer | |
EP2137213A4 (en) | Methods and compositions for treating prostate cancer | |
EP2088862A4 (en) | Cancer treatment method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091203 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100617 |
|
17Q | First examination report despatched |
Effective date: 20111221 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/53 20060101AFI20130516BHEP Ipc: G01N 33/574 20060101ALN20130516BHEP |
|
INTG | Intention to grant announced |
Effective date: 20130617 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 642916 Country of ref document: AT Kind code of ref document: T Effective date: 20131215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008028992 Country of ref document: DE Effective date: 20140130 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20131127 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 642916 Country of ref document: AT Kind code of ref document: T Effective date: 20131127 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140227 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140327 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140327 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008028992 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20140806 Year of fee payment: 7 |
|
26N | No opposition filed |
Effective date: 20140828 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20140806 Year of fee payment: 7 Ref country code: FR Payment date: 20140808 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008028992 Country of ref document: DE Effective date: 20140828 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140508 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140531 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140531 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140508 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602008028992 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20150508 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20160129 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150508 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20151201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131127 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080508 |